ClinicalTrials.gg

Program

PF-07328948

Also written as “Low Dose PF-07328948”, “Medium Dose PF-07328948” and “High Dose PF-07328948”.

In Pfizer's pipeline, Branched chain ketoacid dehydrogenase kinase (BDK) inhibitor. Its studies are mostly in Heart Failure · Renal Insufficiency, led by Pfizer.

Furthest: phase 2, since May 19, 20258 company-led studies, 3 open or runningNext primary completion: Feb 23, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer83 open or runningphase 2since May 19, 2025Oct 13, 2022Feb 23, 2027phase 1 · NCT07269301
  • Named in Pfizer’s own pipeline as PF-07328948, phase 2, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 13, 2022First study: phase 1 study in HealthyFirst studyNCT05654181 · 20 enrolled · United States
  2. Mar 29, 2023Phase 1 study in HealthyNCT05807490 · 86 enrolled · United States, Belgium
  3. Feb 14, 2025Phase 1 study in Healthy AdultsNCT06837259 · 26 enrolled · Belgium
  4. May 19, 2025Phase 2 study in Heart FailureNCT06991257 · 620 planned · United States, Argentina, Brazil and more
  5. Nov 25, 2025Phase 1 study in Hepatic ImpairmentNCT07269301 · 26 planned · United States
  6. Dec 18, 2025Phase 1 study in Renal InsufficiencyNCT07315360 · 28 planned · United States
  7. Mar 3, 20262 phase 1 studiesNCT07455240, NCT07508228
  8. Oct 23, 2026Primary completion moved from 2027-11-16 to 2028-05-08Date moved laterphase 2 · +6 months · NCT06991257

Ahead

  1. Feb 23, 2027Primary completion: phase 1 study in Hepatic ImpairmentNCT07269301
  2. Mar 13, 2027Primary completion: phase 1 study in Renal InsufficiencyNCT07315360
  3. May 8, 2028Primary completion: phase 2 study in Heart FailureNCT06991257

TargetBeta

“Branched chain ketoacid dehydrogenase kinase (BDK) inhibitor”the company's pipeline, read by Claude · source
“A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN ORAL BRANCHED-CHAIN KETOACID DEHYDROGENASE KINASE INHIBITOR, PF-07328948, IN ADULTS WITH HEART FAILURE (BRANCH-HF)”study text, read by Claude · the study

Other programs on BCKDK

ProgramCompanyFurthest phaseStudies
IVPF-07328948Pfizerphase 11
ORALPF-07328948Pfizerphase 11

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07508228Healthy · United States1CompletedJul 10, 20268
NCT07455240Healthy Participant · China1CompletedApr 15, 202610
NCT07315360Renal Insufficiency · United States1RecruitingMar 13, 202728
NCT07269301Hepatic Impairment · United States1RecruitingFeb 23, 202726
NCT06991257Heart Failure · United States, Argentina, Brazil and more2RecruitingMay 8, 2028620
NCT06837259Healthy Adults · Belgium1CompletedJun 11, 202526
NCT05807490Healthy · United States, Belgium1CompletedJul 10, 202486
NCT05654181Healthy · United States1CompletedMay 3, 202320

How it is read

Names in the registry

  • “PF-07328948”, 17 entries
  • “Low Dose PF-07328948”, 1 entry
  • “Medium Dose PF-07328948”, 1 entry
  • “High Dose PF-07328948”, 1 entry
  • “Oral Unlabeled PF-07328948”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.